Newsletter

Stay up to date on all things atrial fibrillation. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

January 24, 2020

Overview

This study aims to survey patients with atrial fibrillation in order to understand direct-acting oral anticoagulant (DOAC) treatment from the patient’s perspective. Records of patient prescription fills will be obtained and aspects of the DOAC dose, such as frequency of use and amount, will be examined.

 

Study Information

560 subjects will be enrolled in the study. The primary purpose of the trial is observation. The study began on April 8, 2019 and is estimated to be completed by April 8, 2020.

 

Inclusion Criteria

 

Retrospective Analysis:

  • NVAF documented in at least 2 claims between January 2015 and December 2016
  • CHA2DS2-VASc scores of 2 or higher

 

Prospective Analysis:

  • Patient Analysis: All patients in ResearchMatch with diagnosed AF.
  • Provider Analysis: All providers who contributed at least 25 AF patients treated with DOACs to the Symphony claims dataset. All provider specialties (i.e. cardiology, primary care, and other), as well as provider types (i.e. physician, physician extender, and nurse practitioner) will be included.

 

Exclusion Criteria

 

Retrospective Analysis:

  • Patients with bioprosthetic or mechanical valves in the mitral position.
  • Patients with any of the following missing data: age, sex, body weight, serum creatinine, and any data required for DOAC dosing.
  • Patients with mitral stenosis.
  • Patients without 12-month follow-up data.

 

Prospective Analysis:

  • Provider Analysis: All providers who contributed less than 25 AF patients treated with DOACs to the Symphony claims dataset.
  • Patient Analysis: Patients unwilling or unable to consent.

 

Location

This study will take place at Duke University, Durham, North Carolina, United States, 27701. If you have any questions, please contact Laura Webb at 919-668-8977 / laura.webb@duke.edu.

 

Sponsors / Collaborators

This study is sponsored by Duke University and Bristol-Myers Squibb. The principal investigator is Tracy Y Wang of the MD Duke Clinical Research Institute at Duke University.

View All Clinical Trials

Clinical Trials

iCLAS for Persistent Atrial Fibrillation

This study aims to evaluate the safety of the Adagio AF Cryoablation System (iCLAS™) for ablation treatment of persistent atrial fibrillation.…

Esophageal Deviation in Atrial Fibrillation Ablation

Ablation treatment in the posterior wall of the left atrium can cause thermal injury to the esophagus, which is a very common occurrence. The goal…

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter

The goal of this study is to compare heart rate control (heart rate <110 beats per minute) at 2 hours after taking the medication diltiazem…

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

The goal of this study is to determine the long term success of non-paroxysmal ablation to treat atrial fibrillation using three different…

The Genetic Basis for Atrial Fibrillation

Veteran patients with atrial fibrillation will be examined for common genetic polymorphisms, and identify…

Liraglutide Effect in Atrial Fibrillation

The goal of this study is to use a medication called Liraglutide to reduce fat deposits surrounding the heart, and…

Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation

The goal of this study is to see how electrogram morphology recurrence (EMR) mapping works on patients with atrial…

High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation

The goal of the study is to find a correlation between FIRM targeted sites and micro-anatomic fibrotic tracks. Patients will first undergo a…

Send this to a friend